Variation in the Aquaretic Efficacy of Tolvaptan in Healthy Adults
Phase of Trial: Phase IV
Latest Information Update: 03 Oct 2016
Price : $35 *
At a glance
- Drugs Tolvaptan (Primary) ; Sodium chloride
- Indications Autosomal dominant polycystic kidney disease; Cardiac oedema; Hyponatraemia; Renal failure
- Focus Pharmacodynamics; Pharmacokinetics
- 26 Sep 2016 Status changed from recruiting to completed.
- 26 Feb 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
- 12 Nov 2013 New trial record